Carboplatin in combination with etoposide for advanced small cell lung cancer complicated with idiopathic interstitial pneumonia: a single-arm phase II study
Abstract Background Acute exacerbation (AEx) of interstitial pneumonia is the most common lethal adverse event related to the pharmacological treatment of patients with lung cancer complicated with interstitial pneumonia. Although small cell lung cancer (SCLC) is linked to poor prognosis, it exhibit...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Pulmonary Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12890-024-03459-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841545003314184192 |
|---|---|
| author | Masaru Matsumoto Yuji Minegishi Katsuyuki Higa Aya Fukuizumi Naomi Onda Susumu Takeuchi Akihiko Miyanaga Akihiko Gemma Masahiro Seike |
| author_facet | Masaru Matsumoto Yuji Minegishi Katsuyuki Higa Aya Fukuizumi Naomi Onda Susumu Takeuchi Akihiko Miyanaga Akihiko Gemma Masahiro Seike |
| author_sort | Masaru Matsumoto |
| collection | DOAJ |
| description | Abstract Background Acute exacerbation (AEx) of interstitial pneumonia is the most common lethal adverse event related to the pharmacological treatment of patients with lung cancer complicated with interstitial pneumonia. Although small cell lung cancer (SCLC) is linked to poor prognosis, it exhibits good response to chemotherapy. Few previous research studies have investigated the safety and efficacy of treatment for advanced SCLC complicated with idiopathic interstitial pneumonia (IIP). We conducted a single-arm phase II study to evaluate the safety and efficacy of carboplatin plus etoposide for the treatment of patients with SCLC complicated with IIP. Methods Chemotherapy-naïve patients with advanced SCLC complicated with IIP were enrolled. Patients received carboplatin every 21–28 days at a dose of area under the curve 4–6 on day 1 and etoposide at a dose of 80–100 mg/m2 on days 1–3. Results Thirty-one patients were enrolled between December 2009 and December 2022. A median of four cycles of carboplatin plus etoposide were administered. Acute exacerbation of idiopathic interstitial pneumonia was not observed; the rate of AEx was 0% (95% confidence interval [CI]: 0–9.6%, p = 0.038). The objective response rate was 83.9% (95% CI: 82.5–85.2). The median progression-free survival and overall survival were 5.9 (95% CI: 4.7–6.8) months and 14.0 (95% CI: 7.6–27.6) months, respectively. The 1-year survival rate was 61% (95% CI 41–76). Conclusions The carboplatin plus etoposide treatment was tolerable and effective in SCLC patients complicated with IIP. |
| format | Article |
| id | doaj-art-ccb942086bbf46839433097a5902f93f |
| institution | Kabale University |
| issn | 1471-2466 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pulmonary Medicine |
| spelling | doaj-art-ccb942086bbf46839433097a5902f93f2025-01-12T12:06:37ZengBMCBMC Pulmonary Medicine1471-24662025-01-012511810.1186/s12890-024-03459-yCarboplatin in combination with etoposide for advanced small cell lung cancer complicated with idiopathic interstitial pneumonia: a single-arm phase II studyMasaru Matsumoto0Yuji Minegishi1Katsuyuki Higa2Aya Fukuizumi3Naomi Onda4Susumu Takeuchi5Akihiko Miyanaga6Akihiko Gemma7Masahiro Seike8Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical SchoolDepartment of Respiratory Medicine, Mitsui Memorial HospitalDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical SchoolDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical SchoolDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical SchoolDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical SchoolDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical SchoolDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical SchoolDepartment of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical SchoolAbstract Background Acute exacerbation (AEx) of interstitial pneumonia is the most common lethal adverse event related to the pharmacological treatment of patients with lung cancer complicated with interstitial pneumonia. Although small cell lung cancer (SCLC) is linked to poor prognosis, it exhibits good response to chemotherapy. Few previous research studies have investigated the safety and efficacy of treatment for advanced SCLC complicated with idiopathic interstitial pneumonia (IIP). We conducted a single-arm phase II study to evaluate the safety and efficacy of carboplatin plus etoposide for the treatment of patients with SCLC complicated with IIP. Methods Chemotherapy-naïve patients with advanced SCLC complicated with IIP were enrolled. Patients received carboplatin every 21–28 days at a dose of area under the curve 4–6 on day 1 and etoposide at a dose of 80–100 mg/m2 on days 1–3. Results Thirty-one patients were enrolled between December 2009 and December 2022. A median of four cycles of carboplatin plus etoposide were administered. Acute exacerbation of idiopathic interstitial pneumonia was not observed; the rate of AEx was 0% (95% confidence interval [CI]: 0–9.6%, p = 0.038). The objective response rate was 83.9% (95% CI: 82.5–85.2). The median progression-free survival and overall survival were 5.9 (95% CI: 4.7–6.8) months and 14.0 (95% CI: 7.6–27.6) months, respectively. The 1-year survival rate was 61% (95% CI 41–76). Conclusions The carboplatin plus etoposide treatment was tolerable and effective in SCLC patients complicated with IIP.https://doi.org/10.1186/s12890-024-03459-yIdiopathic interstitial pneumoniaIdiopathic pulmonary fibrosisAcute exacerbationChemotherapySmall cell lung cancer |
| spellingShingle | Masaru Matsumoto Yuji Minegishi Katsuyuki Higa Aya Fukuizumi Naomi Onda Susumu Takeuchi Akihiko Miyanaga Akihiko Gemma Masahiro Seike Carboplatin in combination with etoposide for advanced small cell lung cancer complicated with idiopathic interstitial pneumonia: a single-arm phase II study BMC Pulmonary Medicine Idiopathic interstitial pneumonia Idiopathic pulmonary fibrosis Acute exacerbation Chemotherapy Small cell lung cancer |
| title | Carboplatin in combination with etoposide for advanced small cell lung cancer complicated with idiopathic interstitial pneumonia: a single-arm phase II study |
| title_full | Carboplatin in combination with etoposide for advanced small cell lung cancer complicated with idiopathic interstitial pneumonia: a single-arm phase II study |
| title_fullStr | Carboplatin in combination with etoposide for advanced small cell lung cancer complicated with idiopathic interstitial pneumonia: a single-arm phase II study |
| title_full_unstemmed | Carboplatin in combination with etoposide for advanced small cell lung cancer complicated with idiopathic interstitial pneumonia: a single-arm phase II study |
| title_short | Carboplatin in combination with etoposide for advanced small cell lung cancer complicated with idiopathic interstitial pneumonia: a single-arm phase II study |
| title_sort | carboplatin in combination with etoposide for advanced small cell lung cancer complicated with idiopathic interstitial pneumonia a single arm phase ii study |
| topic | Idiopathic interstitial pneumonia Idiopathic pulmonary fibrosis Acute exacerbation Chemotherapy Small cell lung cancer |
| url | https://doi.org/10.1186/s12890-024-03459-y |
| work_keys_str_mv | AT masarumatsumoto carboplatinincombinationwithetoposideforadvancedsmallcelllungcancercomplicatedwithidiopathicinterstitialpneumoniaasinglearmphaseiistudy AT yujiminegishi carboplatinincombinationwithetoposideforadvancedsmallcelllungcancercomplicatedwithidiopathicinterstitialpneumoniaasinglearmphaseiistudy AT katsuyukihiga carboplatinincombinationwithetoposideforadvancedsmallcelllungcancercomplicatedwithidiopathicinterstitialpneumoniaasinglearmphaseiistudy AT ayafukuizumi carboplatinincombinationwithetoposideforadvancedsmallcelllungcancercomplicatedwithidiopathicinterstitialpneumoniaasinglearmphaseiistudy AT naomionda carboplatinincombinationwithetoposideforadvancedsmallcelllungcancercomplicatedwithidiopathicinterstitialpneumoniaasinglearmphaseiistudy AT susumutakeuchi carboplatinincombinationwithetoposideforadvancedsmallcelllungcancercomplicatedwithidiopathicinterstitialpneumoniaasinglearmphaseiistudy AT akihikomiyanaga carboplatinincombinationwithetoposideforadvancedsmallcelllungcancercomplicatedwithidiopathicinterstitialpneumoniaasinglearmphaseiistudy AT akihikogemma carboplatinincombinationwithetoposideforadvancedsmallcelllungcancercomplicatedwithidiopathicinterstitialpneumoniaasinglearmphaseiistudy AT masahiroseike carboplatinincombinationwithetoposideforadvancedsmallcelllungcancercomplicatedwithidiopathicinterstitialpneumoniaasinglearmphaseiistudy |